Sizodon

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sizodon

What is Sizodon? (Overview)

Property Description
Active ingredient Risperidone
Form Tablet, Oral Solution, Injectable Solution
Pharmacological class Atypical Antipsychotic (Second-Generation Antipsychotic)
Common use Mental and mood disorder management
Origin Synthetic, Benzisoxazole derivative

What Type of Medication is Sizodon?

Sizodon is a widely recognized brand name for a prescription-only medication whose core active ingredient is Risperidone. It is fundamentally classified as a psychotropic agent and is definitively categorized as an Atypical Antipsychotic (Second-Generation Antipsychotic or SGA). The medication is structurally designed to help stabilize severe disruptions in mental processing, offering an alternative to older classes of antipsychotics.


Composition and Available Forms

The therapeutic action is derived from Risperidone, which is a synthetic compound chemically identified as a benzisoxazole derivative. Its mechanism involves acting as a selective monoaminergic antagonist, targeting the activity of certain neurotransmitters. Sizodon offers diverse administration options: it is available as conventional oral tablets and an oral solution for flexible dosing, as well as in the distinctive form of oral disintegrating tablets (SizoDON MD). The active substance is also formulated into long-acting injectable solutions for intramuscular (IM) or subcutaneous (SC) use, a feature that provides sustained release.


High-Level Purpose and Core Action

The general purpose of Risperidone therapy, as recognized in clinical practice, is to help achieve stability and clarity of thought by modulating the activity of crucial chemical messengers, notably dopamine and serotonin. This targeted action corrects underlying imbalances that often lead to disorganized thinking or intense emotional responses. The core benefit of this selective monoaminergic antagonist action is the moderation of severe disruptions in thought processes, perception, and emotional regulation, promoting a more balanced neural environment. Its use is typically reserved for complex conditions requiring robust neurochemical stabilization.

Regulatory References

  1. MedlinePlus

What side effects are possible with Sizodon?

The official safety profile of Sizodon, which contains Risperidone, is structured by government regulatory bodies into categories based on frequency and affected physiological systems.

Documented Adverse Reactions

Category Examples from Regulatory Labeling Frequency System-Organ Class
Most Common Effects Headache, Sedation, Somnolence Very Common (ge1/10) Nervous System
Common Effects Parkinsonism, Dizziness, Weight gain, Nausea, Vomiting, Increased Prolactin levels Common (ge1/100 to <1/10) Nervous, Metabolism, Endocrine, GI
Uncommon Effects Cerebrovascular events, Neuroleptic Malignant Syndrome (NMS), Tachycardia Uncommon (ge1/1000 to <1/100) Cardiovascular, Nervous System

Serious Adverse Reactions and Safety Constraints

The prescribing information highlights several clinically significant, though less frequent, serious adverse reactions. These include Neuroleptic Malignant Syndrome (NMS), Tardive Dyskinesia (involuntary movements that increase with duration of treatment), and Cerebrovascular Adverse Events such as stroke or TIA, particularly noted in older adults with dementia-related psychosis. The label also documents the potential for Hyperglycemia and Diabetes Mellitus, requiring metabolic monitoring, and high-level constraints related to Orthostatic Hypotension (dizziness upon standing) which is more likely during initial dose adjustment, and Leukopenia/Agranulocytosis (blood disorders). Population-specific safety notes indicate that pediatric patients may experience increased weight gain and higher prolactin levels, and use in older adults with dementia is associated with an increased risk of death.

Overdose and Emergency Response

A suspected overdose of Sizodon (Risperidone) requires immediate medical attention. The officially documented clinical manifestations largely stem from an exaggeration of the drug's known effects on the central nervous and cardiovascular systems.

Overdose presentations commonly include profound drowsiness and sedation, along with uncontrolled Extrapyramidal Symptoms (EPS) and the potential for seizures. Cardiovascular effects frequently documented are a fast, pounding, or irregular heartbeat (tachycardia) and hypotension. Severe outcomes involve cardiac instability, specifically prolonged QT interval, which carries the risk of serious arrhythmias, and in rare cases, circulatory collapse.

Urgent Help-Seeking: The regulatory guidance mandates that immediate medical assistance be sought for any known or suspected over-ingestion. Emergency services must be contacted immediately if the individual has collapsed, experienced a seizure, or cannot be aroused.

Management & Antidote: Management is entirely symptomatic and supportive. There is no specific antidote known. Treatment includes securing the airway, close medical supervision, and continuous cardiovascular monitoring until the patient fully recovers. For severe EPS, specific anticholinergic agents may be administered as a supportive measure. Pediatric patients may be particularly susceptible to severe EPS, making continuous monitoring essential in this population.

Therapeutic Uses of Sizodon

Quick Facts: Sizodon Therapeutic Uses

  • Treats: Schizophrenia
  • Treats: Acute manic or mixed episodes associated with Bipolar I disorder
  • Treats: Irritability associated with Autistic disorder

Sizodon, which contains the active substance risperidone, is a prescribed medicine used for the management of certain mental health conditions. Its primary use is in the treatment of schizophrenia in adults and adolescents aged 13 and older, a chronic condition that affects thinking, feeling, and behavior.

The medication is also indicated for the short-term treatment of acute manic or mixed episodes associated with Bipolar I disorder, a condition characterized by episodes of intense, elevated, or mixed moods. It may be used alone (monotherapy) or in combination with other mood stabilizers as part of a treatment regimen.

Another approved therapeutic use is for the treatment of irritability symptoms associated with Autistic disorder in children and adolescents aged 5 to 16, addressing symptoms such as aggression, deliberate self-injury, and sudden mood shifts. This medication can assist in symptom control for these specific conditions, but it does not cure them. Individuals should continue taking the medication as directed by a healthcare professional.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Who Can and Cannot Use Sizodon?

Eligibility to use Sizodon (risperidone) is strictly defined by regulatory authorities based on established population-specific criteria and absolute constraints.


Populations for whom use is Contraindicated

The medicine is contraindicated in patients with a known hypersensitivity to risperidone or any excipient in the formulation. Critically, Sizodon is not approved for use in elderly patients with dementia-related psychosis, as this population has a documented increased risk of death.


Age-Related Eligibility and Restrictions

Use is restricted to specific minimum age thresholds for each approved condition, as safety and efficacy are not established below these ages. For example, use for schizophrenia is restricted to patients 13 years and older, and for bipolar mania, 10 years and older.


Conditional Use and Organ Function Limitations

Use is restricted and requires caution in patients with impaired organ function, specifically moderate to severe renal or hepatic impairment. Other populations requiring conditional use include those with pre-existing cardiovascular disease or a history of seizures, and patients with Parkinson’s disease.

For women who are pregnant, use is conditional (benefit must outweigh risk), and the official regulatory position advises that nursing mothers should not breastfeed.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Sizodon (Risperidone) primarily through two mechanisms: pharmacokinetic alterations and pharmacodynamic enhancement.

Documented Pharmacokinetic Interactions

The primary pharmacokinetic interactions involve the CYP enzyme system, which significantly affects drug exposure. Co-administration with potent CYP 2D6 inhibitors, such as Fluoxetine and Paroxetine, increases the plasma concentrations of Risperidone. Conversely, CYP 3A4 enzyme inducers, like Carbamazepine, decrease the plasma concentrations of the active moiety (Risperidone plus 9-hydroxyrisperidone). This requires official caution regarding the resulting drug levels.

Pharmacodynamic Enhancement and Restrictions

Risperidone may have additive CNS effects when co-administered with other Centrally-Acting Drugs, including sedatives and hypnotics. For this reason, co-administration with Alcohol (Ethanol) is formally advised against. The drug's alpha-blocking activity may also enhance the effects of hypotensive agents, increasing the risk of low blood pressure. Additionally, the effects of Dopamine Agonists, such as Levodopa, may be antagonized.

Other Constraints and Considerations

The oral solution should not be mixed with tea or cola, but is compatible with water, coffee, orange juice, or low-fat milk. Furthermore, official labeling notes that patients with severe renal or hepatic impairment require a reduction in starting and subsequent doses due to an increased risk of drug exposure.

Mechanism of Action

Sizodon, whose active moiety is risperidone and its metabolite 9-hydroxyrisperidone (paliperidone), primarily functions as a monoaminergic antagonist within the central nervous system. The drug exhibits its major pharmacodynamic actions through high-affinity binding to and antagonism of the serotonin 5-HT2A receptors and, to a lesser degree, the dopamine D2 receptors. The ratio of 5-HT2A to D2 antagonism is a key mechanistic factor. This blockade of G-protein coupled receptors modulates neurotransmission in specific cerebral pathways, including the mesolimbic and mesocortical systems. Antagonism of 5-HT2A receptors is hypothesized to increase dopamine release in certain cortical regions. The D2 receptor antagonism serves to decrease overall dopaminergic signaling. This combined action modifies the downstream intracellular cascades, particularly those involving cyclic AMP (cAMP) and AKT/GSK-3 pathways. The system-level physiological consequence is the modulation of neurocircuits governing affective and cognitive processing, primarily through combined serotonergic and dopaminergic neurotransmitter rebalancing. Secondary antagonist activity is also observed at alpha1 and alpha2 adrenergic receptors and H1 histamine receptors.

Dosage and Administration Information

Sizodon (risperidone) is administered using specific, officially established protocols that define the route, dose, and frequency of use. The medication is available in two general routes: oral forms (tablets, solution, and orally disintegrating tablets) and a prolonged-release injectable suspension for intramuscular (IM) or subcutaneous (SC) administration.

Oral forms can be taken either once daily or in divided doses, with or without food. When using the oral solution, it must only be mixed with water, coffee, orange juice, or low-fat milk, and is specifically not to be mixed with cola or tea. Conversely, all long-acting injectable forms must be administered by a healthcare professional, typically on a bi-weekly (IM) or monthly (SC) schedule.

Treatment is initiated at a low starting dose and gradually increased in a process called titration. For adults beginning oral treatment for schizophrenia, the typical starting amount is 2 mg daily, with the goal of reaching a maintenance range of 4 to 8 mg per day. Specific dosage adjustments are defined for certain patient groups. For example, in older adults or individuals with renal or hepatic impairment, the starting dose is set lower, often at 0.5 mg twice daily, with dose increases occurring at slower intervals.

When transitioning to the long-acting IM injection, patients must continue taking oral risperidone for the first three weeks to bridge the delay until the injection releases adequate medicine levels. Dose adjustments for the IM injection can only occur after at least four weeks. It is established that the prolonged-release suspension be administered deep into the muscle and never intravenously.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Sizodon

Evidence for Use in Schizophrenia

Research for Sizodon (risperidone) includes numerous short-term randomized controlled trials (RCTs) and longer-term maintenance studies. These were conducted in adults and adolescents aged 13 and older, examining acute symptom changes and exploring long-term symptom recurrence patterns. Researchers studied how symptoms changed over time using standardized scales, such as the Positive and Negative Syndrome Scale (PANSS), and tracked global clinical status. Findings describe patterns observed in symptom scale scores when measured alongside placebo and active comparator medications, with results reported for both oral and long-acting injectable forms.

Evidence for Acute Manic or Mixed Episodes

The evidence for Bipolar I Disorder relies primarily on short-term, placebo-controlled RCTs to explore how symptom scores evolved during acute episodes in adults and children/adolescents aged 10 and older. Studies measured manic symptom intensity using instruments like the Young Mania Rating Scale (YMRS). This evidence provides context for managing conditions associated with acute, disruptive episodes, but follow-up durations are limited to acute management intervals.

Evidence for Managing Irritability in Autistic Disorder

Studies for this indication are based on short-term, placebo-controlled RCTs (typically 8 weeks) in children and adolescents aged 5 to 16. These studies focused on monitoring changes in specific measured behaviors, such as aggression and self-injury, using scales like the Aberrant Behavior Checklist (ABC) Irritability subscale. Research highlights short-term measured changes in these targeted behaviors. The findings primarily relate to the symptom of irritability and do not provide controlled evidence regarding the core characteristics of Autistic Disorder.

Research Gaps and What Remains Uncertain

Across all indications, a primary limitation is that many efficacy trials have limited follow-up durations, meaning long-term effects are not fully established. Data for certain groups, such as older adults with schizophrenia or adults with Autistic Disorder, remain insufficient. For pediatric groups, the long-term effects on physical development are not fully characterized.

Key Studies & References

  1. Risperidone versus placebo for schizophrenia (Cochrane Review)
  2. Annotation of FDA Label for risperidone and CYP2D6 (General Regulatory and PK information)

Frequently Asked Questions (FAQ)

Common questions about Sizodon (FAQ)

Q: Is Sizodon known to cause weight gain?

A: Weight gain is a common side effect and metabolic change reported in clinical studies, according to official product information. Greater increases have been noted in some patient groups, such as children and adolescents. Official documentation indicates that weight and other metabolic factors may require regular monitoring during treatment.


Q: Can Sizodon be taken with anti-anxiety medicine?

A: Sizodon is known to have potential additive central nervous system (CNS) effects when used with other centrally-acting drugs, which may include certain anti-anxiety medications. Official information notes that co-administration may be associated with an increased risk of side effects like sedation or excessive drowsiness.


Q: Will Sizodon change my personality?

A: Sizodon is an atypical antipsychotic that works by modulating the activity of chemical messengers like dopamine and serotonin. Its mechanism of action is described as assisting in the stabilization of thought processes, perception, and emotional regulation. This targeted action is associated with modifications in thinking and behavior related to the condition being treated.


Q: What happens when you stop taking Sizodon?

A: Official product information notes that abrupt discontinuation of this medication is not generally recommended. Suddenly stopping may be associated with withdrawal effects or a potential return of original symptoms (rebound). Any decision to stop or change the dose is handled by a healthcare professional through a gradual reduction plan.


Q: Can pregnant or breastfeeding women use Sizodon?

A: Use during pregnancy is conditional, based on regulatory criteria. Official documentation notes that newborns exposed during the third trimester may be at risk for movement and/or withdrawal symptoms after birth. Small amounts of the medicine may pass into breast milk, and regulatory guidance suggests that nursing mothers should typically avoid breastfeeding while on this medicine.


Q: Is Sizodon a controlled substance?

A: Risperidone, the active ingredient in Sizodon, is generally not classified as a controlled substance by US federal law. This classification indicates that the medicine is not associated with the same potential for abuse or dependency as scheduled medications.


Q: What is the general expectation for how long someone stays on Sizodon?

A: Official guidance indicates a treatment philosophy focused on using the lowest effective dose for the shortest duration necessary to achieve a satisfactory response. The need for continued treatment is subject to periodic reassessment by a healthcare provider, particularly because certain long-term risks are associated with increased duration of use.


Q: Can I stop taking Sizodon suddenly?

A: Official product information notes that abrupt discontinuation of this medication is not generally recommended. A sudden reduction may be associated with withdrawal symptoms or a return of original symptoms. Changes to the dose are managed gradually and under the supervision of a healthcare professional.


Q: Can Sizodon be used to manage anxiety?

A: The officially approved uses of Sizodon, according to regulatory labeling, are for the treatment of schizophrenia, manic or mixed episodes of bipolar disorder, and irritability associated with autistic disorder. Anxiety is not listed as an approved indication in the official labeling.


Q: Does Sizodon have a risk of addiction?

A: Sizodon is not classified as a controlled substance, and the official labeling does not state that the medication has a risk of addiction or dependency.


Q: Can Sizodon interact with herbal supplements?

A: Official information notes that certain herbal products, such as St John's wort and ginkgo biloba, may affect how the drug works or potentially increase side effects. Because some supplements may interfere with the medicine, regulatory documentation suggests informing a healthcare provider about all supplements, including herbal remedies.


Q: How quickly does Sizodon start working after I begin taking it?

A: For oral forms, some initial improvements may be noted within the first one to two weeks of starting treatment. However, it often takes several weeks—typically four to six weeks—to experience the full therapeutic effect. The long-acting injectable forms are described as taking longer to reach full therapeutic levels.


Q: Is it common for people to feel restless when starting Sizodon?

A: Yes, restlessness, medically known as akathisia, is listed as a commonly observed adverse reaction in the official product information. This side effect may be noted during the initial phase of treatment or when a dose adjustment is made.


Q: How long does Sizodon stay in your system?

A: The active substance and its metabolite have a combined elimination half-life of about 24 hours, according to official pharmacokinetic data. While the therapeutic effects of a single oral dose last for about one day, it can take several days for the drug to be fully cleared from the body.


Q: What does the research say about Sizodon's effect on memory?

A: The official product label includes a warning about the potential for cognitive and motor impairment. Conversely, some clinical studies examining the drug in approved conditions have reported changes, including improvements, in specific cognitive domains, such as working memory.


Q: Is it safe to take vitamins while on Sizodon?

A: The product labeling does not specifically list interactions with common vitamins. However, as some supplements may contain ingredients that could potentially affect the medicine, regulatory documentation suggests informing a healthcare provider about the use of any vitamins or dietary supplements.

How should Sizodon be stored and disposed of?

Storage and Disposal of Sizodon (Risperidone)

Sizodon must be stored under specific conditions to maintain stability and effectiveness, based on official regulatory labeling.

Requirement Category Official Storage/Handling Rule
Temperature Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F).
Protection Protect the medication from light, moisture, and heat. The Oral Solution must not be frozen.
Packaging Keep the medicine in its closed, original container. Orally Disintegrating Tablets must stay in their blister pack until use.
Child Safety Store the product out of the sight and reach of children and pets.
Disposal Dispose of unused or expired medicine according to local regulatory requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sizodon found in:

A-Z Index: